Male volunteers aged 18-45 years
Showing 1 - 25 of >10,000
HPV InfectioN, HPV-Related Carcinoma Trial in China (Recombinant 14-Valent Human Papillomavirus Vaccine(Insect Cell), )
Active, not recruiting
- HPV InfectioN
- HPV-Related Carcinoma
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- placebo
-
Nanning, Guangxi, China
- +4 more
Sep 10, 2023
Tuberculosis Infection Trial in Saint Petersburg (TB/Flu-05E vaccine, Placebo)
Active, not recruiting
- Tuberculosis Infection
- TB/Flu-05E vaccine
- Placebo
-
Saint Petersburg, Russian FederationSmorodintsev Research Institute of Influenza
Jul 11, 2023
Respiratory Syncytial Virus Infections Trial in Saint Petersburg (RSV/Flu-01E low dose, RSV/Flu-01E high dose, Placebo)
Active, not recruiting
- Respiratory Syncytial Virus Infections
- RSV/Flu-01E low dose
- +2 more
-
Saint Petersburg, Russian FederationSmorodintsev Research Institute of Influenza
Jul 24, 2023
Fragile X Syndrome Trial (BPN14770/ zatolmilast, Placebo)
Not yet recruiting
- Fragile X Syndrome
- BPN14770/ zatolmilast
- Placebo
- (no location specified)
Apr 27, 2022
Hepatitis B Trial in Cambridge (GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine
Recruiting
- Hepatitis B
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide
- +4 more
-
Cambridge, United KingdomGSK Investigational Site
Jan 12, 2023
Malaria Trial in Bagamoyo (SumayaVac-1(SUM-101), Verorab, CHMI)
Not yet recruiting
- Malaria
- SumayaVac-1(SUM-101)
- +2 more
-
Bagamoyo, TanzaniaIfakara Health Institute
Dec 1, 2022
Traumatic Brain Injury, Cerebral Edema Trial (ABX-101 1mg, ABX-101 2mg)
Not yet recruiting
- Traumatic Brain Injury
- Cerebral Edema
- ABX-101 1mg
- ABX-101 2mg
- (no location specified)
Oct 20, 2023
Cervical Cancer, Genital Wart, CIN1 Trial (Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine
Not yet recruiting
- Cervical Cancer
- +11 more
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
- Placebo
- (no location specified)
Oct 17, 2022
![](/image/sponsor/federal_budgetary_research_institution_state_research_center_of_virology_and_biotechnology_"vector")
Smallpox, Monkeypox, Cowpox Trial in Koltsovo, Novosibirsk (VAC?6 vaccine (107 PFU), VAC?6 vaccine (106 PFU), Live Smallpox
Completed
- Smallpox
- +3 more
- VAC∆6 vaccine (10⁷ PFU)
- +3 more
-
Koltsovo, Novosibirsk Region, Russian Federation
- +1 more
Apr 25, 2023
Tuberculosis Trial in Saint Petersburg (GamTBvac, Placebo)
Recruiting
- Tuberculosis
- GamTBvac
- Placebo
-
Saint Petersburg, Russian FederationCity hospital #40
Jan 20, 2022
Smallpox, Monkeypox, Cowpox Trial in Novosibirsk (VAC?6 vaccine - ?nce at a dose of 106 PFU, VAC?6 vaccine - once at a dose of
Completed
- Smallpox
- +3 more
- VAC∆6 vaccine - оnce at a dose of 10⁶ PFU
- +3 more
-
Novosibirsk, Koltsovo, Novosibirsk Region, Russian FederationFederal State Budgetary Healthcare Institution - Medical and San
Feb 28, 2023
Human Papillomavirus Infection Trial in Kunming (Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus
Active, not recruiting
- Human Papillomavirus Infection
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli)
- GARDASIL® 9
-
Kunming, Yunnan, ChinaYunnan Center for Disease Prevention and Control
Dec 23, 2022
Hemophilia A Trial (Fitusiran (SAR439774), Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin
Not yet recruiting
- Hemophilia A
- Fitusiran (SAR439774)
- +3 more
- (no location specified)
Nov 17, 2023
COVID-19, Coronavirus Infections, Respiratory Tract Infections Trial in Russian Federation (Subunit recombinant vaccine for the
Active, not recruiting
- COVID-19
- +3 more
- Subunit recombinant vaccine for the prevention of coronavirus infection
- Placebo
-
Moscow, Russian Federation
- +5 more
Feb 9, 2023
Clostridium Infections Trial in Gent (C. difficile investigational vaccine based on the F2 antigen (GSK2904545A), C. difficile
Completed
- Clostridium Infections
- C. difficile investigational vaccine based on the F2 antigen (GSK2904545A)
- +2 more
-
Gent, BelgiumGSK Investigational Site
Jun 9, 2022
Dengue, Dengue Fever, Dengue Hemorrhagic Fever Trial in India (Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus,
Completed
- Dengue
- +2 more
- Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus
- Placebo: NaCl 0.9% solution
-
Bangalore, Karnataka, India
- +4 more
Mar 15, 2022
Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
Not yet recruiting
- Moderate to Severe Chronic Peripheral Neuropathic Pain (PNP) Due to Postherpetic Neuralgia (PHN) or Peripheral Nerve Injury
- IncobotulinumtoxinA
- Placebo
- (no location specified)
Oct 13, 2023
Influenza Trial in Perm (Inactivated Split Influenza Vaccine, Placebo)
Completed
- Influenza
- Inactivated Split Influenza Vaccine
- Placebo
-
Perm, Russian FederationPerm State Medical University named after academician E.A. Wagne
Dec 16, 2021
Tuberculosis Trial (GSK3036656, Bedaquiline, Delamanid)
Recruiting
- Tuberculosis
- GSK3036656
- +3 more
-
Cape Town, South AfricaGSK Investigational Site
Jan 24, 2023
Interventional, Prevention, Randomized Trial in Nanjing (SCT1000, Gardasil®9, Gardasil®)
Recruiting
- Interventional
- +2 more
- SCT1000
- +3 more
-
Nanjing, Jiangsu, ChinaGuanyun Country CDC
Oct 21, 2021
Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata Trial in Nanjing, Chengdu (Nonavalent HPV vaccine,
Active, not recruiting
- Cervical Intraepithelial Neoplasia
- +2 more
- Nonavalent HPV vaccine
- Bivalent HPV vaccine
-
Nanjing, Jiangsu, China
- +1 more
Feb 10, 2022